Thiopental inhibits lipopolysaccharide-induced tissue factor expression

Anesthesia and Analgesia

Volumn 109, Issue 1, 2009, Pages 109-113

  Hartmann, Matthias ^a   Özlügedik, Semih ^b   Peters, Juergen ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE SITE INHIBITED FACTOR VIIA; BLOOD CLOTTING INHIBITOR; CYCLOHEXIMIDE; LIPOPOLYSACCHARIDE; THIOPENTAL; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; BLOOD SAMPLING; CALCIFICATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOMODULATION; MONOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; THROMBOELASTOGRAPHY; BIOSYNTHESIS; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PHYSIOLOGY;

BLOOD COAGULATION; HUMANS; LIPOPOLYSACCHARIDES; MONOCYTES; THIOPENTAL; THROMBOPLASTIN;

EID: 67650663933     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ane.0b013e3181a27cfb     Document Type: Article

References (27)

1. Opal SM. Interactions between coagulation and inflammation. Scand J Infect Dis 2003;35:545-54
2. Dempfle CE. Coagulopathy of sepsis. Thromb Haemost 2004; 91:213-24
3. Bakhtiari K, Meijers JC, de Jonge E, Levi M. Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med 2004;32:2416-21
4. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr. Recombinant human protein C worldwide evaluation in severe sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709
5. Hoffman M, Monroe DM III. A cell-based model of hemostasis. Thromb Haemost 2001;85:958-65
6. Butenas S, Bouchard BA, Brummel-Ziedins KE, Parhami-Seren B, Mann KG. Tissue factor activity in whole blood. Blood 2005;105:2764-70
7. Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak GM, Buchman TG, Karl IE. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999;27:1230-51
8. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999;341:586-92
9. Sucker C, Zacharowski K, Thielmann M, Hartmann M. Heat shock inhibits lipopolysaccharide-induced tissue factor activity in human whole blood. Thromb J 2007;24:5-13
10. Loop T, Liu Z, Humar M, Hoetzel A, Benzing A, Pahl HL, Geiger KK, J Pannen BH. Thiopental inhibits the activation of nuclear factor kappaB. Anesthesiology 2002;96:1202-13
11. Loop T, Humar M, Pischke S, Hoetzel A, Schmidt R, Pahl HL, Geiger KK, Pannen BH. Thiopental inhibits tumor necrosis factor alpha-induced activation of nuclear factor kappaB through suppression of IkappaB kinase activity. Anesthesiology 2003;99:360-7
12. Zacharowski K, Sucker C, Zacharowski P, Hartmann M. Thrombelastography for the monitoring of lipopolysaccharide induced activation of coagulation. Thromb Haemost 2006;95:557-61
13. Ganter MT, Hofer CK. Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg 2008;106:1366-75
14. Sucker C, Zotz RB, Görlinger K, Hartmann M. Rotational thrombelastometry for the bedside monitoring of recombinant hirudin. Acta Anaesthesiol Scand 2008;52:358-62
15. Censarek P, Bobbe A, Grandoch M, Schrör K, Weber AA. Alternatively spliced human tissue factor (asHTF) is not procoagulant. Thromb Haemost 2007;97:11-4
16. Petersen LC. Active-site inhibited seven: mechanism of action including signal transduction. Semin Hematol 2001;38:39-42
17. Yasuda T, Yamaba T, Sawazaki K, Masuyama F, Nadano D, Takeshita H, Kishi K. Postmortem concentrations of thiopental in tissues: a sudden death case. Int J Legal Med 1993;105:239-41
18. Neuwelt EA, Kikuchi K, Hill SA, Lipsky P, Frenkel E. Barbiturate inhibition of lymphocyte function. Differing effects of various barbiturates used to induce coma. J Neuro Surg 1982;56:254-9
19. Eberhardt KE, Thimm BM, Spring A, Maskos WR. Dose-dependent rate of nosocomial pulmonary infection in mechanically ventilated patients with brain oedema receiving barbiturates: a prospective case study. Infection 1992;20:12-8
20. Salman H, Bergman M, Bessler H, Alexandrova S, Beilin B, Djaldetti M. Effect of sodium thiopentone anesthesia on the phagocytic activity of rat peritoneal macrophages. Life Sci 1998;63:2221-6
21. Corrêa-Sales C, Tosta CE, Rizzo LV. The effects of anesthesia with thiopental on T lymphocyte responses to antigen and mitogens in vivo and in vitro. Int J Immunopharmacol 1997;19:117-28
22. Humar M, Pischke SE, Loop T, Hoetzel A, Schmidt R, Klaas C, Pahl HL, Geiger KK, Pannen BH. Barbiturates directly inhibit the calmodulin/calcineurin complex: a novel mechanism of inhibition of nuclear factor of activated T cells. Mol Pharmacol 2004;65:350-61
23. Humar M, Andriopoulos N, Pischke SE, Loop T, Schmidt R, Hoetzel A, Roesslein M, Pahl HL, Geiger KK, Pannen BH. Inhibition of activator protein 1 by barbiturates is mediated by differential effects on mitogen-activated protein kinases and the small G proteins ras and rac-1. J Pharmacol Exp Ther 2004;311:1232-40
24. Keel M, Mica L, Stover J, Stocker R, Trentz O, Härter L. Thiopental-induced apoptosis in lymphocytes is independent of CD95 activation. Anesthesiology 2005;103:576-84
25. Pöschl JM, Leray C, Ruef P, Cazenave JP, Linderkamp O. Endotoxin binding to erythrocyte membrane and erythrocyte deformability in human sepsis and in vitro. Crit Care Med 2003;31:924-8
26. Chaby R. Lipopolysaccharide-binding molecules: transporters, blockers and sensors. Cell Mol Life Sci 2004;61:1697-713
27. Warren HS, Novitsky TJ, Ketchum PA, Roslansky PF, Kania S, Siber GR. Neutralization of bacterial lipopolysaccharides by human plasma. J Clin Microbiol 1985;22:590-5